Futureproofing Pharmaceutical Supplies with ReMediES

Reconfiguring medicines end-to-end supply

Intersys is a proud partner of the Advanced Manufacturing Supply Chain Initiative (AMSCI) ReMediES project consortium. SCAIR® has been an integral part of this innovative collaboration of more than 22 companies led by GlaxoSmithKline and the University of Cambridge’s Institute for Manufacturing. ReMediES aims to remove inefficiencies in pharma supply chains by bringing together a wide range of stakeholders. Leading global contract manufacturing organisations, equipment manufacturers, regulators, knowledge transfer networks and healthcare providers are just some of the groups working together on this pharma supply chain optimisation solution.

An Integrated Commercial Supply Chain Platform

SCAIR® along with its parent company Intersys, have been creating support tools for the development of a more integrated end-to-end pharma supply chain for the ReMediES project. The ReMediES commercial supply chain team is focussed specifically on increasing efficiency in critical stages of supply chains from equipment selection to network integration and risk management.

Key Outcomes of Supply Chain Risk Management Sub Project

Supply chain segmentation and risk characterisation

Supply chain risk exposure assessment

Compare risk profiles, identify approaches for resilient supply network model

Supply Chain Incident monitoring

Development of SCAIR to monitor Natural Disasters and Regulatory Non Compliances in the biopharma industry

Definition and ranking of pharmaceutical supply chain risk universe